Kazutaka Otsuji1, Takeshi Sasaki2, Atsushi Tanaka3, Akiko Kunita3, Masako Ikemura3, Keisuke Matsusaka3,4, Keiichiro Tada1, Masashi Fukayama3, Yasuyuki Seto1,5. 1. Department of Breast and Endocrine Surgery, Faculty of Medicine, University of Tokyo, Tokyo, Japan. 2. Department of Pathology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan. takesasa@m.u-tokyo.ac.jp. 3. Department of Pathology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan. 4. Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan. 5. Department of Stomach and Esophageal Surgery, Faculty of Medicine, University of Tokyo, Tokyo, Japan.
Abstract
PURPOSE: Digital polymerase chain reaction (dPCR) has been used to yield an absolute measure of nucleic acid concentrations. Recently, a new method referred to as droplet digital PCR (ddPCR) has gained attention as a more precise and less subjective assay to quantify DNA amplification. We demonstrated the usefulness of ddPCR to determine HER2 gene amplification of breast cancer. METHODS: In this study, we used ddPCR to measure the HER2 gene copy number in clinical formalin-fixed paraffin-embedded samples of 41 primary breast cancer patients. To improve the accuracy of ddPCR analysis, we also estimated the tumor content ratio (TCR) for each sample. RESULTS: Our determination method for HER2 gene amplification using the ddPCR ratio (ERBB2:ch17cent copy number ratio) combined with the TCR showed high consistency with the conventionally defined HER2 gene status according to ASCO-CAP (American Society of Clinical Oncology/College of American Pathologists) guidelines (P<0.0001, Fisher's exact test). The equivocal area was established by adopting 99% confidence intervals obtained by cell line assays, which made it possible to identify all conventionally HER2-positive cases with our method. In addition, we succeeded in automating a major part of the process from DNA extraction to determination of HER2 gene status. CONCLUSIONS: The introduction of ddPCR to determine the HER2 gene status in breast cancer is feasible for use in clinical practice and might complement or even replace conventional methods of examination in the future.
PURPOSE: Digital polymerase chain reaction (dPCR) has been used to yield an absolute measure of nucleic acid concentrations. Recently, a new method referred to as droplet digital PCR (ddPCR) has gained attention as a more precise and less subjective assay to quantify DNA amplification. We demonstrated the usefulness of ddPCR to determine HER2 gene amplification of breast cancer. METHODS: In this study, we used ddPCR to measure the HER2 gene copy number in clinical formalin-fixed paraffin-embedded samples of 41 primary breast cancerpatients. To improve the accuracy of ddPCR analysis, we also estimated the tumor content ratio (TCR) for each sample. RESULTS: Our determination method for HER2 gene amplification using the ddPCR ratio (ERBB2:ch17cent copy number ratio) combined with the TCR showed high consistency with the conventionally defined HER2 gene status according to ASCO-CAP (American Society of Clinical Oncology/College of American Pathologists) guidelines (P<0.0001, Fisher's exact test). The equivocal area was established by adopting 99% confidence intervals obtained by cell line assays, which made it possible to identify all conventionally HER2-positive cases with our method. In addition, we succeeded in automating a major part of the process from DNA extraction to determination of HER2 gene status. CONCLUSIONS: The introduction of ddPCR to determine the HER2 gene status in breast cancer is feasible for use in clinical practice and might complement or even replace conventional methods of examination in the future.
Entities:
Keywords:
Breast cancer; Digital PCR; Gene amplification; HER2; Tumor content ratio
Authors: Yuefeng Wang; Julia Y S Tsang; Yongmei Cui; Ji Cui; Ying Lin; Songli Zhao; Patrick T W Law; Sai Yin Cheung; Enders K O Ng; Gary M K Tse; Zunfu Ke Journal: Sci Rep Date: 2017-07-28 Impact factor: 4.379
Authors: Eunyoung Lee; Kyoung Joo Lee; Hyein Park; Jin Young Chung; Mi Na Lee; Myung Hee Chang; Jongha Yoo; Hyewon Lee; Sun Young Kong; Hyeon Seok Eom Journal: Ann Lab Med Date: 2018-03 Impact factor: 3.464
Authors: Diego Fernández-Lázaro; Juan Luis García Hernández; Alberto Caballero García; Alfredo Córdova Martínez; Juan Mielgo-Ayuso; Juan Jesús Cruz-Hernández Journal: Diagnostics (Basel) Date: 2020-04-13